dexamethasone + urea + vincristine + doxorubicin + carmustine

Dexamethasone + urea + vincristine + doxorubicin + carmustine is a multi-agent chemotherapy combination used experimentally or off-label in hematologic malignancies, particularly multiple myeloma. It combines the corticosteroid **dexamethasone** for anti-inflammatory and lympholytic effects, **urea** (historically used for hyperosmotic cytolysis in myeloma), vinca alkaloid **vincristine** to inhibit microtubule formation and mitosis, anthracycline **doxorubicin** for DNA intercalation and topoisomerase II inhibition, and nitrosourea alkylating agent **carmustine** (BCNU) for DNA/RNA cross-linking. No standardized brand name or canonical regimen exists for this exact five-drug mix, distinguishing it from common protocols like VAD (vincristine + doxorubicin + dexamethasone) or VBAD (vincristine + BCNU + doxorubicin + dexamethasone), with urea addition suggesting niche applications in resistant disease.